Portfolio company
Antag Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops GIP receptor antagonist therapies to treat patients living with obesity, type 2 diabetes and metabolic disorders.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Alveus Therapeutics
This clinical-stage biotechnology company develops next-generation therapies for obesity and metabolic diseases to provide sustained weight loss for patients.
AdipoPharma
This clinical-stage biotechnology company develops therapeutic peptides to treat insulin resistance and type 2 diabetes for patients with metabolic disorders.
Carmot Therapeutics
This biotechnology company develops drug therapies to treat metabolic diseases, such as obesity and diabetes, for patients with these conditions.
AdipoPharma SAS
This biotech company develops a therapeutic peptide to treat insulin resistance and type 2 diabetes for patients with metabolic diseases.
Tanai Therapeutics
This company develops oral small molecule therapeutics targeting energy expenditure pathways to treat obesity and cardiometabolic diseases for patients.
Adipo Therapeutics
This biopharmaceutical company develops Notch-inhibiting nanoparticle therapies that convert white fat into energy-burning brown fat for patients with obesity and Type 2 diabetes.
Resalis Therapeutics
This company develops non-coding RNA therapies to treat metabolic disorders, including obesity and fatty liver disease, for patients with unmet medical needs.
Develogen
The company develops therapeutics for metabolic and endocrine disorders to assist pharmaceutical partners in treating conditions such as diabetes and obesity.